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Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach;
however, it has shown limited success in some cancers including colorectal cancer
(CRC). The tumor microenvironment (TME) is largely responsible for response to therapy,
and its constituents may provide robust biomarkers for successful immunotherapeutic
approaches. In this study, we performed phenotypical characterization and critical
analyses of key inhibitory ICs and T regulatory cell (Treg)-related markers on CD4+ T
cell subsets in CRC patients, and compared with normal colon tissues and peripheral
blood from the same patients. We also investigated correlations between the levels of
different CD4+ T cell subsets and the clinicopathologic features including disease stage
and tumor budding. We found a significant increase in the levels of CD4+FoxP3+Helios+
T cells, which represent potentially highly immunosuppressive Tregs, in the CRC TME.
Additionally, tumor-infiltrating CD4+ T cells upregulated programmed cell death protein-1
(PD-1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), T cell immunoglobulin
and mucin domain-3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3). We also
characterized the expression of PD-1, CTLA-4, TIM-3, and LAG-3 on different
CD4+FoxP3−/+Helios−/+ T cell subsets. Interestingly, we found that CTLA-4, TIM-3,
and LAG-3 were mainly co-expressed on FoxP3+Helios+ Tregs in the TME. Additionally,
FoxP3high Tregs expressed higher levels of Helios, CTLA-4 and TIM-3 than FoxP3low T
cells. These results highlight the significance of Tregs in the CRC TME and suggest that
Tregs may hamper response to IC blockade in CRC patients, but effects of different IC
inhibition regimes on Treg levels or activity warrants further investigations. We also found
that CD4+CTLA-4+ T cells in circulation are increased in patients with advanced disease
stage. This study simultaneously provides important insights into the differential levels of
CD4+ T cell subpopulations and IC expression in CRC TME, compared to periphery and
associations with clinicopathologic features, which could be used as potential biomarkers
for CRC progression and response to therapy.
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INTRODUCTION
The tumor immune microenvironment (TIME) is largely
accountable for response to immunotherapeutic modalities,
and better analyses of its constituents can help develop
robust biomarkers to identify patients who would respond to
immunotherapy (1). In addition, DNA fragments or tumor cells
budded off from the primary tumor sites may also be detected in
“liquid biopsies” and used as potential biomarkers for initiation
of effective anti-tumor therapies (2, 3).
Colorectal cancer (CRC) is among the leading causes of
cancer-related mortality and morbidity worldwide, affecting
∼1.4 million newly diagnosed patients and causing death in
0.7 million every year (4, 5). Current treatments for primary
and metastatic CRC primarily include laparoscopic surgeries,
radiotherapy, and neoadjuvant and palliative chemotherapies
(6, 7). Immunotherapy regimes however have not had a big
impact on treating CRC as in treating other malignancies.
Nonetheless, pembrolizumab, an immune checkpoint (IC)
inhibitor [anti-programmed cell death protein 1 (PD-1)], was
recently granted Food and Drug Authority (FDA) approval for
treating unresectable or metastatic solid tumors, including CRC,
with microsatellite instability high (MSI-H) or DNA mismatch
repair deficiency (dMMR) (8, 9).
Inhibitory ICs attenuate T cell responses to mediate immune
tolerance (10). These immune-inhibitory pathways are often
employed by tumors to facilitate immune evasion. High
Treg infiltration coupled with high IC expression in the
tumor microenvironment (TME) should further promote tumor
progression due to T cell exhaustion and impaired cytokine
release. Several studies have reported accumulation of highly
suppressive Treg populations and elevated IC expression in the
colorectal TME (11–13). However, accumulation of Tregs in CRC
patients can have opposing effects on prognosis also as it may be
associated with favorable clinical outcomes (14, 15).
In this study, we investigated the immune landscape of
colorectal tumors, compared to normal colon tissues and
peripheral blood from the same patients. We focused our
investigations on CD4+ T cells and on the expression of key
inhibitory ICs and regulatory T cell (Treg)-related markers.
Tumor-specific T cells are a key component of the TME due to
the presence of a multitude of suppressive mechanisms within
the TME, which assist tumor immune evasion. Accumulation
of Tregs within the TME leads to an immune-permissive
microenvironment, favoring uncontrolled tumor growth (16, 17).
Potent anti-tumor immune responses require a shift in balance
between levels of Tregs and T effector cells (Teff) in the TME
(18). Therefore, T cell trafficking and localization into tumor
sites and preferential proliferation and differentiation of tumor-
reactive T cells can facilitate effective immunotherapies (19).
Moreover, T cell inflamed tumors, characterized by existing anti-
tumor T cell responses, are associated with improved clinical
outcomes in CRC patients (11, 20).
We found a significant increase in CD4+ T cells in the
CRC TME, compared with adjacent normal tissue. Moreover,
these CD4+ T cells comprised of potentially suppressive
FoxP3high Treg populations, which co-expressed high levels
of Helios, previously reported as a marker for activated
Tregs (21). Additionally, we found that intratumoral CD4+
T cells upregulate multiple inhibitory ICs including PD-
1, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), T
cell immunoglobulin and mucin domain-3 (TIM-3), and
lymphocyte-activation gene 3 (LAG-3). We also compared the
levels of different CD4+ T cell subsets between CRC patients
presenting with early and advanced stage disease, and between
patients who showed varying tumor budding status. We found
that patients with advanced stage disease have increased CTLA-
4 expression on CD4+ T cells in circulation. Overall, this study
increases our knowledge about the potential use of checkpoint
blockade in CRC patients.
MATERIALS AND METHODS
Sample Collection and Storage
This study was performed under ethical approvals from Qatar
Biomedical Research Institute, Doha, Qatar (Protocol no. 2018-
018) and Hamad Medical Corporation, Doha, Qatar (Protocol
no. MRC-02-18-012). All experiments were performed in
accordance with relevant guidelines and regulations.
Peripheral blood samples were collected in EDTA tubes from
34 CRC patients, and tumor tissues (TT) and paired, adjacent
non-cancerous normal colon tissues (NT) were obtained from
27 out of these 34 patients, who underwent surgery at Hamad
Medical Corporation, Doha, Qatar. All patients included in the
study were treatment-naïve prior to surgery and provided written
informed consent prior to sample collection. Table 1 shows the
clinical and pathological characteristics of the study population.
Peripheral blood mononuclear cells (PBMC) were isolated
from fresh blood by density-gradient centrifugation using
TABLE 1 | Characteristic features of study populations.
CRC patients
Number 34 (27)†
Age (median) 62 (31-96)§
Gender (Male: Female) 24:10
TNM stage
I 6 (1)†
II 10 (10)†
III 15 (13)†
IV 3 (3)†
DNA mismatch repair deficiency (dMMR) 4 (3)†
Tumor budding
Low 13 (11)†
Intermediate 11 (7)†
High 10 (9)†
Histological grade
G2 Moderately differentiated All samples
CRC; Colorectal cancer.
§Median range.
†
Samples used for analyses of tumor-infiltrating immune cells.
Frontiers in Immunology | www.frontiersin.org 2 December 2019 | Volume 10 | Article 2936
Toor et al. CD4+ T Cells in CRC Patients
Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA). PBMC
were frozen in freezing media (50% FBS, 40% RPMI 1640
media and 10% DMSO) at a density of 5 million cells per
1ml in cryovials to be used in batches for subsequent analyses.
Tissue specimens were also stored in freezing media for
subsequent analyses.
Cell Isolation From Colorectal Tumors and
Normal Colon Tissues
Cells were isolated from NT and TT by mechanical
disaggregation. Briefly, tissues frozen in freezing media
were thawed and washed with phosphate-buffered saline (PBS)
and then mechanically cut into small pieces (∼2–4mm) using
a surgical scalpel. Tissue disaggregation was performed on a
gentleMACS dissociator (Miltenyi Biotech, Bergisch Gladbach,
Germany) without using enzymes. The cell suspension was then
passed through a 100µM cell strainer to remove aggregates and
debris. The single cell suspension was washed with PBS and
stained for flow cytometric analyses.
Multi-Parametric Flow Cytometry
PBMC and cells isolated from tissues were washed with PBS
and re-suspended in 100 µl flow cytometry staining buffer
(PBS with 1% FCS and 0.1% sodium azide). Fc receptors (FcR)
were first blocked using FcR Blocker (Miltenyi Biotec). Fixable
Viability Dye eFluor 780 (eBioscience, San Diego, USA) was
added to gate live cells. Cells were then stained with cell surface
antibodies including CD3-Alexa Fluor 700 (clone UCHT-1;
BD Biosciences, Oxford, UK), CD4-phycoerythrin (clone RPA-
T4; BD Biosciences), CD25-Brilliant Violet 650 (clone BC96;
BioLegend, San Diego, USA), PD-1-PE/DazzleTM 594 (clone
EH12.2H7; BioLegend), LAG-3-Brilliant violet 421 (clone T47-
530; BD Biosciences) and TIM-3-Brilliant Violet 711 (clone 7D3;
BD Biosciences) and incubated at 4◦C for 30min. Cells were
then washed twice with flow cytometry staining buffer. For
intracellular staining, cells were incubated at 4◦C for 45min in
fixation/permeabilization buffer (eBioscience). Cells were then
washed twice with permeabilization wash buffer (eBioscience).
Mouse serum (Sigma-Aldrich) and rat serum (Sigma-Aldrich)
were added to block non-specific binding sites for 10min
at 4◦C. Intracellular antibodies including CTLA-4-PerCP-
eFluor 710 (clone 14D3; eBioscience), FoxP3-phycoerythrin
cyanin 7 (PE/Cy7) (clone PCH101; eBioscience) and Helios-
Fluorescein Isothiocyanate (FITC) (clone 22F6; BioLegend)
were then added and cells incubated for another 30min
at 4◦C. Cells were then washed twice with permeabilization
wash buffer (eBioscience), and re-suspended in flow cytometry
staining buffer.
All data were acquired on a BD LSRFortessa X-
20 SORP flow cytometer using BD FACSDiva software
(BD Biosciences) and analyzed on FlowJo V10 software
(FlowJo, Ashland, USA).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 8
software (GraphPad Software, California, USA). One-way Anova
test was performed to check for statistical significance in
grouped analyses. Paired t-tests were performed within groups
on samples that passed the Shapiro-Wilk normality test, while
Wilcoxon matched-pairs signed rank tests were performed on
samples that did not show normal distribution. Unpaired t-tests
were performed for comparisons between groups on normally
distributed data andMann-Whitney tests for samples that did not
show normal distribution. A P > 0.05 was considered statistically
non-significant. The P-values are represented as follows; ∗∗∗P <
0.001, ∗∗P < 0.01, ∗P < 0.05. Data are presented as mean ±
standard error of the mean (SEM).
RESULTS
Increased Levels of CD4+ T Cells in the
Tumor Microenvironment of Colorectal
Cancer Patients
Accumulation of tumor-infiltrating T cells in CRC patients has
been previously reported, and shown to be associated with
favored clinical outcomes (11). We investigated the levels of
CD4+ T cells in circulation, normal colon tissues and in the
TME of CRC patients. The overall levels of circulating CD4+
and CD4− T cells in our cohort were similar (CD4+; 31.4% vs.
CD4−; 31.7%, Figure 1A). In agreement with previous reports,
we found that CD4+ T cells accumulate in colorectal tumors,
compared with normal tissues but were lower compared to
their levels in circulation (PBMC; 31.4 ± 2.0 vs. NILs; 11.5
± 1.0 vs. TILs; 22.0 ± 2.1, Figure 1A). Levels of Teff cells
within the TME can greatly affect cancer progression and
response to therapy (18). Therefore, we focused our subsequent
investigations to perform further phenotypical characterization
of CD4+ T cell subsets to ascertain their role in colorectal
tumor biology.
Tumor-Infiltrating CD4+ T Cells in CRC
Patients Comprise Mainly of Potentially
Suppressive T Regulatory Cells
Tregs constitute an important subset of CD4+ T cells, which
are characterized by high expression of interleukin-2 receptor
alpha chain (CD25) and forkhead box P3 (FoxP3) transcription
factor (22). Moreover, Helios is a key transcription factor, which
regulates FoxP3+ Treg functional stability and it is required
for their inhibitory activity (23). Infiltration of FoxP3+ Tregs
is often associated with poor prognosis and disease progression
(24). We found that the levels of CD4+CD25+, CD4+FoxP3+
and CD4+Helios+ T cells were significantly higher in the
TME, compared with NT and circulation (CD25: PBMC; 5.0
± 0.6 vs. NILs; 2.6 ± 0.4 vs. TILs; 13.0 ± 1.8, FoxP3: 6.5
± 0.7 vs. 9.8 ± 0.8 vs. 26.8 ± 2.8 & Helios: 9.1 ± 0.8 vs.
11.8 ± 1.0 vs. 23.1 ± 2.5, Figures 1B–D). We also found
that Tregs in CRC TME comprise mainly of FoxP3+Helios+
Tregs, which were significantly higher in the TME compared
with normal tissue and periphery (5.7 ± 0.6 vs. 6.6 ± 0.5 vs.
20.5± 2.3, Figure 1E).
FoxP3high Tregs have been previously identified as
suppression-competent, while FoxP3low T cells identified
as non-suppressive Tregs (14). Therefore, we investigated
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FIGURE 1 | Levels of circulating and tumor-infiltrating CD4+ T cells in colorectal cancer patients and expression levels of T regulatory cell-related markers. PBMC
from 34 colorectal cancer (CRC) patients and immune cells isolated from colorectal tumor tissues (TILs) and paired, adjacent non-tumor normal colon tissues (NILs)
from 27 patients were stained for CD4+ T cell markers and Treg-related markers including CD25, FoxP3, and Helios. Representative flow cytometric plots and scatter
plots show the levels of CD3+CD4+ T cells in PBMC, NILs, and TILs from CRC patients (A). Representative flow cytometric and scatter plots show expression levels
of CD25 (B), FoxP3 (C), and Helios (D) in CD4+ T cells in PBMC, NILs, and TILs. Representative flow cytometric plots show FoxP3 and Helios co-expression and
scatter plots show differences in levels of CD4+FoxP3−/+Helios−/+ subsets in PBMC, NILs and TILs (E). ***P < 0.001, **P < 0.01, *P < 0.05.
Helios expression within FoxP3high and FoxP3low populations
to ascertain the potential suppressive characteristics of the
FoxP3+Helios+ subpopulation, accumulated in CRC tumors.
We found that CD4+FoxP3high Tregs express significantly
higher levels of Helios than CD4+FoxP3low cells in PBMC,
NILs, and TILs (PBMC; 58.8 ± 2.6 vs. 88.1 ± 1.7, NILs;
41.4 ± 3.7 vs. 65.1 ± 3.9 & TILs; 58.0 ± 3.5 vs. 80.9 ± 2.3,
Figure 2). Next, we investigated differences in expression levels
of different inhibitory ICs between FoxP3low and FoxP3high
Tregs. Interestingly, we found that CTLA-4 and TIM-3 were also
expressed at significantly higher levels on CD4+FoxP3high Tregs
than CD4+FoxP3low T cells in PBMC, NILs, and TILs (CTLA-4:
PBMC; 15.1 ± 2.7 vs. 36.7 ± 3.6, NILs; 48.5 ± 5.2 vs. 77.6 ± 4.8,
TILs; 64.4 ± 4.7 vs. 88.3 ± 1.5 & TIM-3: PBMC; 0.6 ± 0.1 vs. 1.0
± 0.3, NILs; 11.3 ± 2.5 vs. 22.7 ± 3.6, TILs; 21.6 ± 3.7 vs. 38.2
± 4.7, Figure 2). However, PD-1 did not show any significant
differences in expression levels between CD4+FoxP3low/high
NILs and TILs, but it was significantly lower on CD4+FoxP3high
T cells than CD4+FoxP3low T cells in circulation (PBMC; 27.5±
2.5 vs. 19.1± 2.4, Figure 2).
We also compared the mean fluorescence intensity
(MFI) of the different markers between CD4+FoxP3low
and CD4+FoxP3high Tregs (Figure 2C). We found that the
differences in population frequencies were also reflected in
differences in MFI. The MFI for Helios was significantly higher
in CD4+FoxP3high Tregs than CD4+FoxP3low T cells in PBMC
(1928 ± 36.6 vs. 2253 ± 52.1), NILs (2457 ± 108.2 vs. 2656 ±
163.7) and TILs (2374 ± 97.4 vs. 2759 ± 156.9). CTLA-4 and
TIM-3 also showed similar patterns (CTLA-4: PBMC; 2384 ±
64.5 vs. 2701 ± 73.2, NILs; 2492 ± 221.1 vs. 5197 ± 365.8, TILs;
2922± 188.5 vs. 5797± 501.5 and TIM-3: PBMC; 621± 19.5 vs.
771 ± 44.5, NILs; 1546 ± 84.9 vs. 1889 ± 145.0, TILs; 1708 ±
69.6 vs. 2203 ± 161.2), while PD-1 did not show any significant
differences in MFI between CD4+FoxP3low and CD4+FoxP3high
Tregs in PBMC, NILs and TILs (Figure 2C).
High Expression of Immune Checkpoints
on Intratumoral CD4+ T Cells
Immune checkpoints are expressed on activated or exhausted
T cells (16). To find out the functional state of infiltrating
T cells in the colorectal TME, we investigated IC expression
on different CD4+ T cell subsets. We found that key
inhibitory ICs, including PD-1, CTLA-4, TIM-3 and LAG-
3 were highly expressed on CD4+ TILs (Figure 3). These
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FIGURE 2 | Differences in Helios and immune checkpoint expression on CD4+FoxP3low and CD4+FoxP3high PBMC, NILs, and TILs from CRC patients.
CD4+FoxP3low and CD4+FoxP3high Tregs were gated in PBMC, NILs, and TILs to investigate Helios, PD-1, CTLA-4, and TIM-3 expressions. Representative flow
cytometric plots show gating strategy for defining CD4+FoxP3low/high Tregs and the expression levels of Helios, PD-1, CTLA-4, and TIM-3, in TILs isolated from CRC
patients (A). Scatter plots show differences in expression level (B) and Mean Fluorescence Intensity (MFI) (C) of Helios, PD-1, CTLA-4, and TIM-3 between
CD4+FoxP3low and CD4+FoxP3high PBMC, NILs, and TILs from CRC patients. ***P < 0.001, **P < 0.01.
ICs were expressed at significantly lower levels in periphery
compared to normal colon tissue and showed elevated expression
levels in the TME (PD-1: PBMC; 14.9 ± 1.1 vs. NILs; 48.1
± 4.8 vs. TILs; 57.8 ± 5.7, CTLA-4: 4.8 ± 0.8 vs. 22.7
± 2.4 vs. 45.9 ± 5.7, TIM-3: 0.5 ± 0.1 vs. 7.5 ± 1.0 vs.
23.2 ± 3.2 & LAG-3: 0.4 ± 0.1 vs. 1.8 ± 0.4 vs. 2.7 ±
0.5, Figure 3). Moreover, it is noteworthy that the overall
expression levels of PD-1 were highest in tissues and in
periphery, followed by CTLA-4 and TIM-3, while LAG-3 showed
lowest overall expression on CD4+ T cells compared to other
ICs (Figure 3).
We also investigated co-expression of PD-1 with other
ICs in PBMC, NILs, and TILs. We found that PD-1 was
mainly co-expressed with CTLA-4 and TIM-3 in CD4+ TILs
(Figures 4A,B). In contrast, although CD4+PD-1+LAG-3+ T
cells were significantly higher in NILs and in TILs compared to
PBMC, the majority of CD4+PD-1+ T cells do not co-express
LAG-3 (Figure 4C).
CTLA-4, TIM-3, and LAG-3 Are Mainly
Expressed on FoxP3+Helios+ Tregs in the
Tumor Microenvironment
A plausible approach to evoke potent antitumor immune
responses without triggering autoimmunity is to target
terminally differentiated Tregs (24). Previous studies have
reported overexpression of various ICs on Tregs including
constitutive expression of CTLA-4 (25–27). We wanted to
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FIGURE 3 | Immune checkpoint expression on CD4+ T cells in PBMC, NILs, and TILs from CRC patients. PBMC, NILs, and TILs were stained for CD3, CD4, and key
immune checkpoints. Representative flow cytometric plots and scatter plots show differences in expression levels of PD-1 (A), CTLA-4 (B), TIM-3 (C), and LAG-3 (D)
on CD4+ T cells in PBMC, NILs, and TILs. ***P < 0.001.
identify which Treg subpopulations upregulate inhibitory
ICs in the colorectal TME based on FoxP3 and Helios
expression. We found that key inhibitory ICs are differentially
upregulated on various intratumoral Treg subsets, compared
to CD4+FoxP3−Helios− non-Tregs (Figures 5A–D). In TILs,
PD-1 was mainly expressed on CD4+FoxP3−Helios+ (60.3 ±
4.5) and CD4+FoxP3+Helios− Tregs (59.7 ± 5.5), compared to
CD4+FoxP3+Helios+ (49.5 ± 6.1) and CD4+FoxP3−Helios−
(50.6 ± 5.5) (Figure 5A). CTLA-4 and LAG-3 were mainly
expressed on both CD4+FoxP3+Helios+ (CTLA-4; 78.5 ±
3.8 & LAG-3; 6.8 ± 0.9) and CD4+FoxP3+Helios− Tregs
(CTLA-4; 72.8 ± 4.1 & LAG-3; 6.2 ± 0.8), compared to
CD4+FoxP3−Helios+ TILs (CTLA-4; 48.7 ± 5.6 & LAG-3; 4.4
± 0.9) and CD4+FoxP3−Helios− TILs (CTLA-4; 21.8 ± 3.5 &
LAG-3; 0.5 ± 0.1) (Figures 5B,D). While, TIM-3 was mainly
expressed on CD4+FoxP3+Helios+ TILs (44.5± 4.6), compared
to CD4+FoxP3−Helios+ (22.8 ± 3.4), CD4+FoxP3+Helios−
TILs (25.9 ± 3.4) and CD4+FoxP3−Helios− TILs (5.9 ± 1.8)
(Figure 5C).
Notably, inhibitory ICs showed different expression patterns
on CD4+FoxP3−/+Helios−/+ in periphery. PD-1 was mainly
expressed on CD4+FoxP3+Helios− Tregs in circulation (19.5
± 2.0), followed by CD4+FoxP3−Helios+ T cells (14.0 ±
1.1) and CD4+FoxP3−Helios− T cells (11.3 ± 1.0), while
CD4+FoxP3+Helios+ Tregs showed lowest PD-1 expression
(7.4 ± 0.8) (Figure 5E). CTLA-4 was mainly expressed on
CD4+FoxP3+Helios− (33.8 ± 3.5) and CD4+FoxP3+Helios+
Tregs (30.0 ± 2.7), compared to CD4+FoxP3−Helios+
(10.7 ± 1.6) and CD4+FoxP3−Helios− T cells (1.9 ± 0.3).
TIM-3 was mainly expressed on FoxP3 and/or Helios-
expressing T cells, compared to CD4+FoxP3−Helios− T
cells (0.2 ± 0.1) in circulation (Figure 5E). In addition, no
significant differences were detected in TIM-3 expression
on CD4+FoxP3−Helios+ (1.1 ± 0.2), CD4+FoxP3+Helios+
(1.4 ± 0.4) and CD4+FoxP3+Helios− (1.6 ± 0.4) T cells
in circulation (Figure 5E). In normal colon tissues, PD-
1 expression did not show any significant differences in
CD4+FoxP3−Helios+ (36.4 ± 5.0), CD4+FoxP3+Helios+
(30.2 ± 5.0), CD4+FoxP3+Helios− (33.8 ± 6.4) and
CD4+FoxP3−Helios− (33.3 ± 3.8) NILs (Figure 5F). CTLA-4
was also mainly expressed on CD4+FoxP3+Helios− (43.9 ±
7.0) and CD4+FoxP3+Helios+ NILs (37.9 ± 6.1), compared to
CD4+FoxP3−Helios+ (20.5 ± 4.8) and CD4+FoxP3−Helios−
NILs (11.1 ± 1.9). In contrast, TIM-3 was mainly expressed
on CD4+FoxP3+Helios+ NILs (16.6 ± 2.9), followed by
CD4+FoxP3+Helios− (8.7 ± 2.1) and CD4+FoxP3−Helios+
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FIGURE 4 | Immune checkpoints co-expression on CD4+ T cells. PBMC, NILs, and TILs isolated from CRC patients were stained for CD3, CD4, and immune
checkpoints. Representative flow cytometric and scatter plots show differences in co-expression levels of PD-1−/+CTLA-4−/+ (A), PD-1−/+TIM-3−/+ (B), and
PD-1−/+LAG-3−/+ (C) on CD4+ T cells in PBMC, NILs, and TILs. ***P < 0.001.
(2.1 ± 0.7) NILs, while CD4+FoxP3−Helios− NILs showed
minimal TIM-3 expression (1.0 ± 0.2) (Figure 5F). Of
note, there were no conclusive results to identify the
CD4+FoxP3+/−Helios+/− subset with highest LAG-3
expression due to weak overall LAG-3 expression in periphery
(data not shown).
Visualization of overall CD4+ T cell infiltrates in CRC
tumors and periphery is depicted in Figure 6. We generated t-
Distributed Stochastic Neighbor Embedding (tSNE) plots from
various Treg-related markers and inhibitory ICs in PBMC, NILs,
and TILs from CRC patients. We confirmed that FoxP3, Helios,
PD-1, TIM-3, and CTLA-4 expression levels are increased in
CD4+ TILs, while CD4+ T cells showed lower Treg-related
markers and IC expression in PBMC and NILs (Figure 6A). In
addition, CD4+ TILs co-expressed multiple ICs compared to
PBMC and NILs (Figure 6B). Helios, PD-1 and TIM-3 were also
expressed on CD4− T cells and showed elevated expression on
CD4− TILs (Figure 6B).
Patients With Advanced Stage Disease
Have Higher Levels of CD4+CTLA-4+ T
Cells in Circulation
We compared the levels of CD4+ T cell subsets in circulation,
NILs and TILs between CRC patients presenting with early
and advanced pathologic stages (Figures 7A–C). We combined
patients with stages I and II (PBMC; n = 15, NILs/TILs;
n = 11) and compared with those with stages III and IV
advanced stage (PBMC; n = 19, NILs/TILs; n = 16). We
found that the levels of circulating CD4+ T cells were similar
between patients with early or advanced stages. Intestinally,
there was a significant increase in levels of CD4+CTL-4+ T
cells only in circulation of patients with advanced stage (4.0
± 1.3 vs. 5.4 ± 1.1, Figure 7A). The constitutive expression
of CTLA-4 on CD4+ Tregs suggests correlation of elevated
levels of CTLA-4+ Tregs with CRC disease progression.
However, other T cell subsets, including CD4+FoxP3+ Tregs,
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FIGURE 5 | Immune checkpoint expression on FoxP3 and Helios subsets in CD4+ TILs, PBMC, and NILs. TILs isolated from CRC patients were stained for CD3,
CD4, immune checkpoints and FoxP3 and Helios. Representative flow cytometric plots and scatter plots show differences in expression levels of PD-1 (A), CTLA-4
(B), TIM-3 (C), and LAG-3 (D) in CD4+FoxP3−/+Helios−/+ TILs subsets. Scatter plots show differences in expression levels of PD-1, CTLA-4, and TIM-3 in
CD4+FoxP3−/+Helios−/+ PBMC (E) and NILs (F) from CRC patients. ***P < 0.001, **P < 0.01, *P < 0.05.
did not show any correlation with disease progression (data
not shown).
Levels of CD4+ T Cells Are Similar in
Patients Exhibiting Varying Tumor Budding
Status
Tumor budding in CRC has been associated with poor disease
outcomes in various studies (28). We divided our cohort into
three groups based on tumor budding data; low (PBMC; n = 13,
NILs/TILs; n = 11), intermediate (PBMC; n = 11, NILs/TILs;
n = 7) and high (PBMC; n = 10, NILs/TILs; n = 9), and
compared levels of various T cell subsets in circulation, NILs and
TILs between them. We did not find any significant differences
between CD4+ T cell subsets in circulation, NILs or TILs
(Figures 7D–F). Moreover, there were no significant differences
in the levels of other CD4+ T cell subsets, including TIM-3-
expressing CD4+ T cells, between patients with different tumor
budding status (data not shown).
DISCUSSION
Studies have reported correlations between increased T cell
infiltration of various tumors and improved responses to
therapies and favorable disease outcomes (29). Interferon-γ-
secreting cytotoxic T cells, T-helper 1 (Th1) cells, natural killer
cells and macrophages polarized to an M1 phenotype and DC1
dendritic cells are largely associated with favorable anti-tumor
immune responses (30–32). While, Th2 cells, M2 macrophages,
DC2 dendritic cells, myeloid derived suppressor cells (MDSC)
and IL-10 and TGFβ releasing FoxP3+ Tregs are associated with
immunosuppression (33, 34).
In CRC patients, high infiltration of CD3+ T cells, Th1
cells and cytotoxic T cells in the tumor center and invasive
margins correlated with improved overall survivals and disease-
free survivals, while lower T cell density was associated with poor
prognosis (35, 36). In addition, high CD8+ tumor-infiltrating
T cells were shown to be a favorable prognostic factor for
right-sided colon tumors (37) and increased levels of CD4+
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FIGURE 6 | Visualizing expression of Treg-related markers and immune checkpoint expression in PBMC, NILs, and TILs from CRC patients. Flow cytometric data
from PBMC, NILs, and TILs were merged to create single t-Distributed Stochastic Neighbor Embedding (tSNE) maps. Cells (dots) are plotted according to expression
of CD4, CD25, FoxP3, Helios, PD-1, TIM-3, CTLA-4, and LAG-3 in PBMC, NILs, and TILs from CRC patients (A). tSNE maps show combined co-expression of the
different Treg-related markers and immune checkpoints on CD4+ and CD4− T cells in PBMC, NILs and TILs from CRC patients (B).
and CD8+ T cells in colorectal TME were shown to correlate
with improved response to chemo-radiotherapy (38). Moreover,
the presence of effector memory T cells within CRC tumors,
defined by the presence of CD3, CD8, CD45RO, CCR7, CD28,
and CD27 expression, was associated with absence of signs of
early metastatic invasion (39). Therefore, evidence of an active
immune response in the CRC TME was shown to be associated
with prolonged survival (39).
We found that CD4+ T cells were significantly higher in
colorectal tumors, compared with normal colon tissues. CD4+
T cells in circulation comprise mainly of naïve T cells, while
in tissues comprise mainly of memory T cells. Galon et al.
proposed that the immune landscape of CRC tumors can be
considered as a robust predictor of patient survival and it may
be used for histopahlogical classification of CRC tumors; they
found that patients with high immune cell densities within
the tumor and at invasive margins did not show recurrence
(40). Importantly, transcriptomic profiling of immune subsets
found in CRC tumors confirmed that immune cell infiltrates can
affect disease outcomes as patients with prolonged disease-free
survivals had distinct expression of genes related to cytotoxic
T cells, T helper molecules and chemokine-related genes
than patients with adverse disease outcomes (35). Therefore,
comprehensive investigations are required to ascertain the role
of immune cells in the TME and their effects on clinical
outcomes of CRC patients. We reported high levels of different
ICs and Treg-related markers in CRC TME, which would
suggest their potential roles in carcinogenesis. Mechanisms of
expansion/proliferation or trafficking of these CD4+ T cell
subsets into tumor sites warrants further investigations.
Pre-existing Tregs in the TME expand upon antigen-specific
activation in the presence of TGF-β and IL-10, which are
found at high levels within the TME (41, 42). We found that
CD4+CD25+FoxP3+ Tregs accumulate in colorectal tumors at
significantly higher levels, compared to periphery and adjacent
colon normal tissues. Moreover, these Tregs expressed high
levels of Helios, indicative of highly suppressive and stable Treg
function (43). Studies have shown that FoxP3+Helios+ Tregs
have enhanced immunosuppressive characteristics, compared
with FoxP3+Helios− Tregs (44–46).
Majority of studies have associated Tregs with poor clinical
outcomes in different cancers including CRC (47, 48), however
some studies have also associated these with better prognosis in
CRC patients (49–51). Saito et al. proposed that these results
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FIGURE 7 | Levels of CD4+ and CD4+CTLA-4+ T cells in CRC patients with different staging and tumor budding. Patients were divided into two groups based on
pathologic staging; early stage (Stage I and II) and advanced stage (Stage III and IV). Scatter plots show differences in levels of CD4+ and CD4+CTLA-4+ T cells in
PBMC (A), NILs (B), and TILs (C) between CRC patients with early and advanced stages. Patients were also divided into three groups based on degree of tumor
budding; low, intermediate and high. Scatter plots show differences in levels of CD4+ T cells in PBMC (D), NILs (E), and TILs (F) between CRC patients. *P < 0.05.
could be attributed to different subsets of tumor-infiltrating
FoxP3+ Tregs, which include FoxP3high and FoxP3low Tregs;
the former representing stable FoxP3 expression, while FoxP3low
non-suppressive Tregs secrete inflammatory cytokines and
henceforth may be associated with improved clinical outcomes in
CRC (14). In addition, it has been shown that tumor-infiltrating
FoxP3highCD45RA− effector Tregs, which express PD-1, are
highly activated, express high levels of CTLA-4 and are associated
with hyper progressive disease in patients with advanced gastric
cancer (52). Based on these findings, we investigated differences
in Helios and other IC expression between FoxP3low and
FoxP3high PBMC,NILs, and TILs.We found that FoxP3high Tregs
express Helios at significantly higher levels than FoxP3low T cells
in the TME and in periphery of CRC patients, strengthening
that Helios is a vital marker for suppressive Tregs in CRC.
Additionally, FoxP3high Tregs also showed significantly higher IC
expression in the TME, indicating their highly activated states.
ICs are expressed on activated T cells including both Teff cells
and Tregs (10), they are also highly expressed on dysfunctional
and exhausted T cells, characterized by defective effector function
and proliferation (53, 54). IC expression on T cells represent
early activation or exhaustion due to prolonged exposure to
residing antigens, which ultimately attenuate their effector
functionality (55). Studies have shown that multiple inhibitory
receptors are associated with T cell exhaustion but the specific
mechanisms that administer their transcriptional and epigenetic
development or their phenotypic identification remain to be fully
elucidated. Notably, recent studies have proposed the HMG-
box transcription factor TOX as a critical regulator of T cell
exhaustion, which may be used to identify exhausted T cells (56).
Additionally, investigating expression of other key transcription
factors associated with T cell exhaustion, such as NFAT, EOMES,
T-bet, FOXO1, and FOXP1 (55) in different IC-expressing CD4+
T cells would also ascertain their exhaustive states.
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CTLA-4 is constitutively expressed on Tregs and modulates
their functionality (57). Additionally, Tregs in the TME
upregulate other multiple ICs including PD-1, LAG-3, TIM-3,
and TIGIT (58); FoxP3+ Tregs expressing TIM-3/LAG-3 and
PD-1 were shown to be highly suppressive (25, 59). TIM-3
expression on Tregs has been previously reported to show higher
ability to suppress Th17 cells than TIM-3− Tregs, while both
can effectively suppress Th1 proliferation (60). We found that in
the CRC TME, TIM-3 is mainly expressed on FoxP3+Helios+
Tregs, hence more potent suppressors of Th17 responses. In
addition, we showed that PD-1, TIM-3, CTLA-4, and LAG-
3 were mainly expressed on CD4+FoxP3+ Tregs in the TME,
further reinforcing the suppressive role of these cells in the
TME. tSNE representation, which enables visualization of high-
dimensional data on a single bivariate plot, also confirmed the
accumulation of Tregs and elevated IC expression on CD4+ T
cells in the TME. Moreover, high IC expression corresponded
with Treg populations in TILs.
Tumor budding is associated with vascular invasion
and prognosis in colorectal cancer (61, 62). This study
cohort consisted of CRC displaying different tumor budding
characteristics, ranging from low to high. However, we did not
find any differences in the levels of CD4+ T cells in periphery
or TME across all patients with varying tumor budding status;
thereby suggesting CD4+ T cells are not associated with tumor
budding in CRC.
Following the accomplishments of PD-1 and CTLA-4
blockade, TIM-3 and LAG-3 are currently being explored in
various pre-clinical and clinical trials to promote effective
anti-tumor immunity for clinical benefits (63). This study
provides comprehensive and simultaneous comparisons of
expression levels of different ICs on CD4+ T cells, including
Tregs, in the TME and periphery of CRC patients. IC
inhibitors significantly improved survival in patients with
MSI-H metastatic CRC. However, a significant proportion of
patients show minimal response and do not benefit from
ICIs (64). Additionally, the percentage of CRC patients who
exhibit MSI-H/dMMR is generally low, around 12–15% of
all cases (65), like in this study cohort (Table 1). Equating
immune profiles of these patients with those who do not show
microsatellite instability to find differences would therefore
require a much larger patient pool. Moreover, the long-
term prognosis of patients with advanced stage CRC remains
poor despite efforts to develop novel chemotherapeutic and
targeted therapy regimens. Predictive biomarkers for successful
IC inhibition with clinical benefits are a necessity in such
instances. Expression of ICs and their ligands in the TME
have been proposed as such predictive biomarkers (66), and
better understanding of the immune components can therefore
assist in identifying robust biomarkers for response to therapy
and also assist in targeted-therapies, tailor made on individual
patient basis.
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